Semaglutide Intermediate P29 (GLP-1(9-37)) Specifications
| Items | Characteristic |
| Source | E.Coli |
| Appearances | White or off-white lyophilized powder |
| Solubility | Soluble in water (pH11.0-pH11.5) |
| Purity | ≥90.0% |
| Loss on drying | ≤10.0% |
| Content | Calculated on a dry basis, the content of semaglutide intermediate 29 peptide should be ≥ 90.0% |
The data should be subject to test report of products.
Key Advantages for Semaglutide API Production
Our Semaglutide Intermediate P29 offers superior quality and reliability:
Animal-Free Production & Maximum Safety:
Manufactured without animal-derived materials, eliminating the risk of contamination from animal viruses and exogenous factors.
Ensures a high safety profile, compliant with strict biopharma industry requirements.
GMP-Compliant Manufacturing:
The entire production process is carried out under strict GMP conditions (Good Manufacturing Practice).
Complete Quality Documentation:
We provide full support documentation, including the Certificate of Analysis (CoA) and necessary regulatory files.
Commercial Scale & Customization:
Supplied on a proven commercial scale with flexible packaging and customization options to meet your bulk production needs.
Product Usage and Handling Information
Primary Usage
This product is used exclusively for the production of Semaglutide API.
Recommended Synthesis Method
1. Dissolve an appropriate amount of this Semaglutide intermediate P29 powder in purified water to achieve a concentration of 5-10 mg/ml.
2. Adjust the pH to 11.0-11.5 to ensure complete dissolution and clarification.
3. Optimize the reaction system for Semaglutide synthesis.
Handling, Transport, and Storage Stability
Storage Stability: Can be stored stably for 24 months at -15 ℃ or below in a sealed, dark place.
Transportation Stability: Transported in an ice pack to maintain activity.
Handling Notice: Avoid prolonged storage in liquid conditions; use immediately once dissolved. Avoid strong acids, strong bases, strong oxidants, and high concentrations of organic solvents that cause protein denaturation.
Notice and Disclaimer
Avoid long time storage in liquid condition, please use it as soon as possible once it was dissolved.
Avoid strong acids, strong bases, strong oxidants, high concentrations of organic solvents and other reagents that can easily cause protein denaturation.
The product is for research and production only and should not be used for diagnosis or treatment of animals or humans.
Semaglutide Clinical Context
Semaglutide Intermediate 29 Peptide, also known as Semaglutide 29 peptide backbone, Semaglutide Intermediate P29 or GLP-1(9-37), is the key intermediate of the synthesis of Semaglutide API.
Semaglutide is a 2nd Generation GLP-1RA drug. In Dec., 2019, Semaglutide injection (brand name: Ozempic, 4mg/3ml) was approved by FDA to improve glycemic control in adults with type 2 diabetes. In Jun. 2021, Semaglutide injection (brand name Wegovy, 2.4mg/dose) was approved by FDA to treat obesity (BMI>30kg/m2) and overweight (BMI≥27kg/m2).
In Sep. 2019, oral Semaglutide (brand name, Rybelsus, 3ma, 7mg and 14ma/ tablet) was approved by FDA for the treatment of type 2 diabetes. Meanwhile, Rybelsus 25mg and 50mg strengths showed clear effects in Phase II and Phase III clinical trials for weight loss or non-alcoholic fatty liver (NASH). In Oct., 2023, phase II clinical trials for patients with insufficiency type II diabetes and chronic kidney disease were terminated early due to excellent efficacy.
Need High-Quality Semaglutide API Intermediate?
Contact Gene-Biocon Now for Bulk Pricing and Full COA!
